#USA #Long Beach, California #Canine Lymphoma #Anivive #LAVERDIA

Anivive Lifesciences Achieves FDA Approval for Laverdia®

Anivive Lifesciences has reached an important milestone with the full FDA approval of Laverdia® (verdinexor tablets), which provides a groundbreaking treatment option for canine lymphoma. This announcement, made on June 26, 2026, signifies the first oral, at-home therapeutic alternative approved for this prevalent cancer affecting dogs, a significant advancement for veterinarians and pet owners alike.

The Importance of Laverdia®

Canine lymphoma represents a major concern in veterinary oncology, being one of the most frequently diagnosed cancers in dogs. Laverdia offers a promising and affordable approach for managing this illness, tailored for ease of administration in a home environment. Not only does it make treatment more accessible, but it also equips veterinarians with the necessary tools to enhance the quality of life for afflicted pets.

The FDA approval is a result of Anivive’s dedication to leveraging modern technology in drug development. Utilizing their AI-powered AniviveSELECT platform, the company successfully identified and prioritized verdinexor, linking existing human medicines with pertinent veterinary applications. Following the identification phase, the AniviveTRIAL framework played a crucial role in accelerating clinical trials by effectively matching and recruiting eligible dogs, contributing significantly to study enrollment and culminating in the timely approval of Laverdia.

Behind the Science of Laverdia

Laverdia operates as an XPO1 inhibitor, disrupting the proteins that facilitate cancer cell survival within the body. This innovative mechanism of action has been a potential game-changer, showcasing promising results and a favorable safety profile in initial clinical evaluations. According to Dr. David Bruyette, Chief Medical Officer at Anivive, this provides veterinarians with greater flexibility in customizing treatment protocols tailored to each dog’s unique needs, ultimately leading to improved outcomes.

Collaboration that Counts

The journey of Laverdia's approval began with the conditional authorization granted by the FDA in 2021, allowing Anivive to market the drug during the fulfillment of outstanding clinical requirements. In a landmark partnership, Anivive teamed up with Dechra Veterinary Products in 2022 to distribute Laverdia in the U.S. With the recent full approval, Laverdia will now be accessible through Dechra nationwide, supported by comprehensive educational resources and dosing guidance — ensuring that healthcare teams are well-equipped to provide the best care for their patients.

A Future of Expanding Access

The success of Laverdia in the U.S. marks just the beginning. Anivive is ambitiously pursuing regulatory approvals for Laverdia in several international markets, including Australia, Brazil, Canada, Europe, Japan, and the United Kingdom. Not stopping there, Anivive also aims to explore the application of verdinexor in other cancers affecting dogs and cats, while expanding its diagnostic tool, SearchLight DNA™, aiming to redefine cancer care for pets.

The veterinary oncology market is set for substantial growth, projected to reach approximately USD $4.86 billion by 2034, with a steady growth rate of 12.14%. In light of these promising trends, Anivive’s innovative model and commitment to enhancing animal health may play a pivotal role in shaping the future landscape of veterinary medicine.

To delve deeper into the specifics of Laverdia and the cutting-edge approach Anivive takes in drug development, you can visit Laverdia and Anivive.

About Anivive Lifesciences

Anivive Lifesciences specializes in the development of veterinary medicines through an integrated platform harnessing artificial intelligence and rigorous clinical research. From identifying human drugs suitable for repurposing in veterinary care to streamlining enrollment for clinical trials, Anivive is pioneering new treatments in veterinary oncology and beyond.

About Dechra

Dechra is recognized as a global leader in veterinary pharmaceuticals, devoted to advancing the understanding and treatment of animal health. For more information, visit Dechra.